{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:22:46Z","timestamp":1790022166500,"version":"4.0.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Sciensano"},{"name":"Belgian Institute for Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Herpesvirus infections [e.g. Epstein\u2013Barr virus (EBV) or cytomegalovirus (CMV)] are a major cause of mortality and morbidity in post-transplant patients despite antiviral therapy, with the emergence of drug resistance further complicating patients\u2019 care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the dynamics and drug resistance of simultaneous EBV and CMV reactivations in an HSCT recipient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Twenty-two samples derived from blood, one sample from bone marrow and one sample from colon biopsy over an 8\u2005month period while under different anti-CMV treatments were analysed. CMV, EBV and torque teno virus (TTV) DNA loads were determined and viral dynamics were investigated by genotyping of the CMV and EBV genes involved in drug resistance by Sanger sequencing (prospectively) and next-generation sequencing (NGS) (retrospectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>EBV reactivation was seen simultaneously with CMV reactivation and rising of TTV DNA load, suggesting increased immunosuppression. A reduction of EBV viraemia under maribavir was observed. Emergence of the CMV DNA polymerase (DP) L773V MDR mutation occurred following antiviral treatment and was subsequently replaced by the CMV UL97 protein kinase (PK) ganciclovir resistance A594P mutation, which could be detected earlier by NGS than by Sanger sequencing. At 273\u2005days post-transplantation, the patient still had active CMV\/EBV co-reactivation, with CMV being refractory to antiviral therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The use of NGS and Sanger sequencing revealed evolution of CMV drug resistance under antiviral treatment. Our findings highlight the potential of maribavir to treat EBV infection and the difficulties in managing CMV\/EBV co-reactivation in immunocompromised hosts.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf243","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:57:26Z","timestamp":1751529446000},"page":"2474-2483","source":"Crossref","is-referenced-by-count":2,"title":["Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-3116","authenticated-orcid":false,"given":"Martyna","family":"Pociupany","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Molecular, Structural, and Translational Virology Research Group, Rega Institute for Medical Research, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gillemot","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Molecular, Structural, and Translational Virology Research Group, Rega Institute for Medical Research, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Georgala","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Institut Jules Bordet - Universit\u00e9 Libre de Bruxelles (ULB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Molecular, Structural, and Translational Virology Research Group, Rega Institute for Medical Research, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Molecular, Structural, and Translational Virology Research Group, Rega Institute for Medical Research, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2025090219521897800_dkaf243-B1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40011-011-0008-7","article-title":"Viral infections in immunocompromised hosts","volume":"82","author":"Ramamurthy","year":"2012","journal-title":"Proc Natl Acad Sci India Sect B Biol Sci"},{"key":"2025090219521897800_dkaf243-B2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/JLB.4MR1221-452R","article-title":"Molecular and immune interactions between \u03b2- and \u03b3-herpesviruses in the immunocompromised host","volume":"112","author":"S\u00e1nchez-Ponce","year":"2022","journal-title":"J Leukoc Biol"},{"key":"2025090219521897800_dkaf243-B3","doi-asserted-by":"publisher","first-page":"e13396","DOI":"10.1111\/tid.13396","article-title":"Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: a systematic review of the literature","volume":"22","author":"Anderson-Smits","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"2025090219521897800_dkaf243-B4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CCO.0000000000000885","article-title":"Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment","volume":"34","author":"Dierickx","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"2025090219521897800_dkaf243-B5","doi-asserted-by":"publisher","first-page":"818167","DOI":"10.3389\/fcimb.2022.818167","article-title":"Association between cytomegalovirus and Epstein-Barr virus co-reactivation and hematopoietic stem cell transplantation","volume":"12","author":"Li","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2025090219521897800_dkaf243-B6","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00277-021-04642-5","article-title":"Epstein\u2013Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes","volume":"100","author":"Ding","year":"2021","journal-title":"Ann Hematol"},{"key":"2025090219521897800_dkaf243-B7","doi-asserted-by":"publisher","first-page":"116270","DOI":"10.1016\/j.bcp.2024.116270","article-title":"Treatment of Epstein-Barr virus infection in immunocompromised patients","volume":"225","author":"Pociupany","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"2025090219521897800_dkaf243-B8","doi-asserted-by":"publisher","first-page":"8253","DOI":"10.1021\/bi801179f","article-title":"DNA polymerases as therapeutic targets","volume":"47","author":"Berdis","year":"2008","journal-title":"Biochemistry"},{"key":"2025090219521897800_dkaf243-B9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","article-title":"Antiviral therapies for herpesviruses: current agents and new directions","volume":"40","author":"Poole","year":"2018","journal-title":"Clin Ther"},{"key":"2025090219521897800_dkaf243-B10","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.3390\/v6114731","article-title":"KSHV targeted therapy: an update on inhibitors of viral lytic replication","volume":"6","author":"Coen","year":"2014","journal-title":"Viruses"},{"key":"2025090219521897800_dkaf243-B11","doi-asserted-by":"publisher","first-page":"115322","DOI":"10.1016\/j.bcp.2022.115322","article-title":"Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives","volume":"206","author":"Schalkwijk","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"2025090219521897800_dkaf243-B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/cancers10060197","article-title":"Antiviral drugs for EBV","volume":"10","author":"Pagano","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025090219521897800_dkaf243-B13","doi-asserted-by":"publisher","first-page":"e13696","DOI":"10.1111\/cts.13696","article-title":"Maribavir: mechanism of action, clinical, and translational science","volume":"17","author":"Sun","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2025090219521897800_dkaf243-B14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/jclinpath-2019-205822","article-title":"Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors","volume":"72","author":"Kerr","year":"2019","journal-title":"J Clin Pathol"},{"key":"2025090219521897800_dkaf243-B15","doi-asserted-by":"publisher","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"2025090219521897800_dkaf243-B16","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/bcp.13292","article-title":"Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025090219521897800_dkaf243-B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-med-042921-124739","article-title":"Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients","volume":"74","author":"Saullo","year":"2023","journal-title":"Annu Rev Med"},{"key":"2025090219521897800_dkaf243-B18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/microorganisms13020326","article-title":"Viral infections in HSCT recipients with post-transplant lymphoproliferative disorder: the role of torque teno virus as a marker of immune functions","volume":"13","author":"Pociupany","year":"2025","journal-title":"Microorganisms"},{"key":"2025090219521897800_dkaf243-B19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.bbmt.2019.11.002","article-title":"The value of torque teno virus (TTV) as a marker for the degree of immunosuppression in adult patients after hematopoietic stem cell transplantation (HSCT): TTV as a biomarker in adult patients after HSCT","volume":"26","author":"Schmitz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025090219521897800_dkaf243-B20","doi-asserted-by":"publisher","first-page":"1168400","DOI":"10.3389\/fmed.2023.1168400","article-title":"Understanding torquetenovirus (TTV) as an immune marker","volume":"10","author":"Gore","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025090219521897800_dkaf243-B21","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3389\/fimmu.2020.00998","article-title":"Torque teno virus as a potential biomarker for complications and survival after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Pradier","year":"2020","journal-title":"Front Immunol"},{"key":"2025090219521897800_dkaf243-B22","doi-asserted-by":"publisher","first-page":"e13778","DOI":"10.1111\/tid.13778","article-title":"Viruses, friends, and foes: the case of torque teno virus and the net state of immunosuppression","volume":"24","author":"Redondo","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2025090219521897800_dkaf243-B23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.kint.2020.08.010","article-title":"Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death","volume":"99","author":"Dujardin","year":"2021","journal-title":"Kidney Int"},{"key":"2025090219521897800_dkaf243-B24","doi-asserted-by":"publisher","first-page":"ofy230","DOI":"10.1093\/ofid\/ofy230","article-title":"Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation","volume":"5","author":"Meesing","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025090219521897800_dkaf243-B25","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.transproceed.2023.04.042","article-title":"Peripheral blood absolute lymphocyte count as a predictor of cytomegalovirus infection in kidney transplant recipients","volume":"55","author":"Shiina","year":"2023","journal-title":"Transplant Proc"},{"key":"2025090219521897800_dkaf243-B26","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025090219521897800_dkaf243-B27","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/diagnostics14222523","article-title":"Cytomegalovirus infections in hematopoietic stem cell transplant: moving beyond molecular diagnostics to immunodiagnostics","volume":"14","author":"Gupta","year":"2024","journal-title":"Diagnostics"},{"key":"2025090219521897800_dkaf243-B28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0195-6701(96)90010-9","article-title":"Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options","volume":"33","author":"Reusser","year":"1996","journal-title":"J Hosp Infect"},{"key":"2025090219521897800_dkaf243-B29","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1128\/AAC.03957-14","article-title":"Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses","volume":"58","author":"Coen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090219521897800_dkaf243-B30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1399-3062.2006.00186.x","article-title":"Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient","volume":"9","author":"Andrei","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"2025090219521897800_dkaf243-B31","doi-asserted-by":"publisher","first-page":"982111","DOI":"10.3389\/fbioe.2023.982111","article-title":"Methods to improve the accuracy of next-generation sequencing","volume":"11","author":"Cheng","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"2025090219521897800_dkaf243-B32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12864-015-1806-8","article-title":"Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes","volume":"16","author":"Peng","year":"2015","journal-title":"BMC Genomics"},{"key":"2025090219521897800_dkaf243-B33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025090219521897800_dkaf243-B34","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1128\/AAC.03214-14","article-title":"Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090219521897800_dkaf243-B35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J Infect Dis"},{"key":"2025090219521897800_dkaf243-B36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/jmv.20150","article-title":"Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations","volume":"74","author":"Scott","year":"2004","journal-title":"J Med Virol"},{"key":"2025090219521897800_dkaf243-B37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial","volume":"209","author":"Chou","year":"2014","journal-title":"J Infect Dis"},{"key":"2025090219521897800_dkaf243-B38","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1128\/AAC.00736-07","article-title":"Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens","volume":"51","author":"Chou","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090219521897800_dkaf243-B39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1128\/JCM.43.1.208-213.2005","article-title":"How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients","volume":"43","author":"Springer","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2025090219521897800_dkaf243-B40","doi-asserted-by":"publisher","first-page":"569381","DOI":"10.3389\/fimmu.2020.569381","article-title":"Viral infections in HSCT: detection, monitoring, clinical management, and immunologic implications","volume":"11","author":"Annaloro","year":"2021","journal-title":"Front Immunol"},{"key":"2025090219521897800_dkaf243-B41","doi-asserted-by":"publisher","first-page":"101539","DOI":"10.1016\/j.trim.2022.101539","article-title":"Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: from antiviral drugs to virus-specific T cells","volume":"71","author":"Ivana","year":"2022","journal-title":"Transpl Immunol"},{"key":"2025090219521897800_dkaf243-B42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2478\/ahp-2020-0005","article-title":"Prophylaxis vs preemptive therapy in prevention of CMV infection: new insight on prophylactic strategy after allogeneic hematopoietic cell transplantation","volume":"51","author":"Styczy\u0144ski","year":"2020","journal-title":"Acta Haematol Pol"},{"key":"2025090219521897800_dkaf243-B43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics (Sao Paulo)"},{"key":"2025090219521897800_dkaf243-B44","doi-asserted-by":"publisher","first-page":"106860","DOI":"10.1016\/j.ijantimicag.2023.106860","article-title":"Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants","volume":"62","author":"Fatima","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2025090219521897800_dkaf243-B45","doi-asserted-by":"publisher","first-page":"874601","DOI":"10.1155\/2012\/874601","article-title":"Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"2012","author":"Barkam","year":"2012","journal-title":"Bone Marrow Res"},{"key":"2025090219521897800_dkaf243-B46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: first global approval","volume":"78","author":"Kim","year":"2018","journal-title":"Drugs"},{"key":"2025090219521897800_dkaf243-B47","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025090219521897800_dkaf243-B48","doi-asserted-by":"publisher","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"2025090219521897800_dkaf243-B49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/molecules24050997","article-title":"Novel therapeutics for Epstein\u2013Barr virus","volume":"24","author":"Andrei","year":"2019","journal-title":"Molecules"},{"key":"2025090219521897800_dkaf243-B50","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1128\/JVI.03505-12","article-title":"Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase","volume":"87","author":"Whitehurst","year":"2013","journal-title":"J Virol"},{"key":"2025090219521897800_dkaf243-B51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1386-6532(02)00046-X","article-title":"Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","volume":"26","author":"Mousavi-Jazi","year":"2003","journal-title":"J Clin Virol"},{"key":"2025090219521897800_dkaf243-B52","doi-asserted-by":"publisher","first-page":"105792","DOI":"10.1016\/j.antiviral.2023.105792","article-title":"Ganciclovir and maribavir cross-resistance revisited: relative drug susceptibilities of canonical cytomegalovirus mutants","volume":"222","author":"Chou","year":"2024","journal-title":"Antiviral Res"},{"key":"2025090219521897800_dkaf243-B53","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/v13060985","article-title":"An MHV-68 mutator phenotype mutant virus, confirmed by CRISPR\/cas9-mediated gene editing of the viral DNA polymerase gene, shows reduced viral fitness","volume":"13","author":"Trompet","year":"2021","journal-title":"Viruses"},{"key":"2025090219521897800_dkaf243-B54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/aol-21-33","article-title":"From pathobiology to targeted treatment in Epstein Barr virus related T cell and natural killer cell lymphoproliferative diseases","volume":"5","author":"Glover","year":"2021","journal-title":"Ann Lymphoma"},{"key":"2025090219521897800_dkaf243-B55","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","article-title":"Next-generation sequencing technologies: an overview","volume":"82","author":"Hu","year":"2021","journal-title":"Hum Immunol"},{"key":"2025090219521897800_dkaf243-B56","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.humimm.2021.03.011","article-title":"Challenges in the application of NGS in the clinical laboratory","volume":"82","author":"Yin","year":"2021","journal-title":"Hum Immunol"},{"key":"2025090219521897800_dkaf243-B57","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/v16091465","article-title":"A comparison of Sanger sequencing and amplicon-based next generation sequencing approaches for the detection of HIV-1 drug resistance mutations","volume":"16","author":"Biba","year":"2024","journal-title":"Viruses"},{"key":"2025090219521897800_dkaf243-B58","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1093\/infdis\/jiae414","article-title":"Revealing the unseen: next-generation sequencing for early detection of drug-resistant cytomegalovirus variants upon letermovir prophylaxis failure","volume":"231","author":"N\u00e4gele","year":"2025","journal-title":"J Infect Dis"},{"key":"2025090219521897800_dkaf243-B59","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1038\/s41598-021-85182-w","article-title":"Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes","volume":"11","author":"Arteche-L\u00f3pez","year":"2021","journal-title":"Sci Rep"},{"key":"2025090219521897800_dkaf243-B60","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/humu.22332","article-title":"Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics","volume":"34","author":"Sikkema-Raddatz","year":"2013","journal-title":"Hum Mutat"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2474\/63794472\/dkaf243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2474\/63794472\/dkaf243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:52:22Z","timestamp":1756857142000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/9\/2474\/8206109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf243","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,18]]}}}